RT Journal Article
SR Electronic
A1 Gater, Laura
T1 New Therapies: Vildagliptin
JF MD Conference Express
YR 2006
FD SAGE Publications
VO 6
IS 2
SP 16
OP 16
DO 10.1177/155989770600600208
UL http://mdc.sagepub.com/content/6/2/16.abstract
AB Vildagliptin, is a dipeptdyl peptidase 4 (DPP-4) inhibitor; DPP-4 is the enzyme that degrades glucagon-like peptide-1 (GLP-1). GLP-1 triggers glucose dependent insulin secretion, inhibits the secretion of glucagon, slows gastric emptying, and influences satiety. GLP-1 has a very short half-life, so by inhibiting the action of DPP-4, GLP-1 remains in its active form for a longer period. This article discusses updates on vildagliptin.